Baidu
map

J Am Acad Child Psy:儿童期创伤增加青少年药物滥用风险

2016-06-17 Seven L 译 MedSci原创

发表在 American Academy of Child & Adolescent Psychiatry的研究显示,从人际暴力到车祸的儿童创伤,与非法药物使用风险的增加有关。“虐待和家庭暴力会增加青少年药物滥用的可能性,”哥伦比亚大学的Hannah Carliner硕士说,“我们还发现,童年期创伤如汽车事故、自然灾害和重大疾病,也会导致青少年使用大麻、可卡因和处方药的风险。”为了评估儿童

发表在 American Academy of Child & Adolescent Psychiatry的研究显示,从人际暴力到车祸的儿童创伤,与非法药物使用风险的增加有关。

“虐待和家庭暴力会增加青少年药物滥用的可能性,”哥伦比亚大学的Hannah Carliner硕士说,“我们还发现,童年期创伤如汽车事故、自然灾害和重大疾病,也会导致青少年使用大麻、可卡因和处方药的风险。”

为了评估儿童创伤性事件和非法药物使用之间的潜在关联,研究人员对9956名年龄在13至18岁的青少年的数据进行了研究分析。

潜在的创伤性事件分为人际暴力(身体虐待、物理攻击、抢劫、强奸、性骚扰、跟踪、绑架、家庭暴力);创伤性事故(车祸、其他严重事故、自然或人为的灾难、身体上的疾病、接触有毒化学物质或意外受伤);网络或目睹事件(亲人意外死亡、亲人的痛苦经历或目睹受伤或死亡);其他事件。

总体而言,36%的参与者在11岁之前经历了潜在的创伤性事件。在11岁之前暴露于潜在的创伤性事件会增加使用大麻的风险(RR = 1.5; 95% CI, 1.33-1.69),使用可卡因的风险(RR = 2.78; 95% CI, 1.95-3.97),使用其他药物的风险(RR = 1.9;95% CI,1.37-2.63)以及使用多种药物的风险(RR = 1.74;95% CI,1.37-2.2)。

研究人员发现潜在的创伤性事件和大麻、其他药物、多种药物的使用之间存在一个积极单调的关系。

人际暴力也会增加以下药物的使用风险:大麻(RR = 1.78; 95% CI, 1.54-2.07)、可卡因(RR = 2.64; 95% CI, 1.75-3.98)、非处方药(RR = 2.2; 95% CI, 1.49-3.27)、其他药物(RR = 1.7; 95% CI, 1.12-2.57)和多种药物(RR = 2.31; 95% CI, 1.69-3.15)。

汽车事故和未确定的潜在创伤性事件也与更高的大麻、可卡因和处方药使用风险有关。

“对于童年期创伤性经历所造成的心理伤害应专门予以药物治疗方案,”Carliner说,“对关键时期青春期进行早期干预,可能对健康和福祉有广泛的利益。”

原始出处:


Carliner H, et al. Childhood Trauma and Illicit Drug Use in Adolescence: A Population-Based National Comorbidity Survey Replication–Adolescent Supplement Study .J Am Acad Child Adolesc Psychiatry. 2016;doi:10.1016/j.jaac.2016.05.010.

Childhood trauma increases risk for drug use in adolescence.Healio.June 16, 2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1651821, encodeId=55761651821e4, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Sep 30 13:49:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661935, encodeId=18fc16619359c, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701518, encodeId=03fe1e0151893, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Wed Dec 28 08:49:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783098, encodeId=ba771e830981a, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335101, encodeId=3bc9133510115, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443225, encodeId=57ce14432251e, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
    2016-09-30 lishizhe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1651821, encodeId=55761651821e4, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Sep 30 13:49:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661935, encodeId=18fc16619359c, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701518, encodeId=03fe1e0151893, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Wed Dec 28 08:49:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783098, encodeId=ba771e830981a, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335101, encodeId=3bc9133510115, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443225, encodeId=57ce14432251e, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
    2017-03-03 docwu2019
  3. [GetPortalCommentsPageByObjectIdResponse(id=1651821, encodeId=55761651821e4, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Sep 30 13:49:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661935, encodeId=18fc16619359c, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701518, encodeId=03fe1e0151893, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Wed Dec 28 08:49:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783098, encodeId=ba771e830981a, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335101, encodeId=3bc9133510115, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443225, encodeId=57ce14432251e, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
    2016-12-28 zchen
  4. [GetPortalCommentsPageByObjectIdResponse(id=1651821, encodeId=55761651821e4, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Sep 30 13:49:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661935, encodeId=18fc16619359c, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701518, encodeId=03fe1e0151893, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Wed Dec 28 08:49:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783098, encodeId=ba771e830981a, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335101, encodeId=3bc9133510115, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443225, encodeId=57ce14432251e, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1651821, encodeId=55761651821e4, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Sep 30 13:49:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661935, encodeId=18fc16619359c, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701518, encodeId=03fe1e0151893, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Wed Dec 28 08:49:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783098, encodeId=ba771e830981a, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335101, encodeId=3bc9133510115, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443225, encodeId=57ce14432251e, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1651821, encodeId=55761651821e4, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Sep 30 13:49:00 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661935, encodeId=18fc16619359c, content=<a href='/topic/show?id=260c9e210e' target=_blank style='color:#2F92EE;'>#ILD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9721, encryptionId=260c9e210e, topicName=ILD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701518, encodeId=03fe1e0151893, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Wed Dec 28 08:49:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783098, encodeId=ba771e830981a, content=<a href='/topic/show?id=855a464292' target=_blank style='color:#2F92EE;'>#child#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4642, encryptionId=855a464292, topicName=child)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Fri Mar 03 17:49:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335101, encodeId=3bc9133510115, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443225, encodeId=57ce14432251e, content=<a href='/topic/show?id=51748e807c7' target=_blank style='color:#2F92EE;'>#药物滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87807, encryptionId=51748e807c7, topicName=药物滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c1a5038471, createdName=ms6323715314570549, createdTime=Sun Jun 19 14:49:00 CST 2016, time=2016-06-19, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map